{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T21:22:10Z","timestamp":1793827330809,"version":"4.6.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T00:00:00Z","timestamp":1661212800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R44AI055229"],"award-info":[{"award-number":["5R44AI055229"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["5R44AI058375"],"award-info":[{"award-number":["5R44AI058375"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"},{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 03.902"],"award-info":[{"award-number":["TTU 03.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009139","name":"Deutsches Zentrum f\u00fcr Infektionsforschung","doi-asserted-by":"publisher","award":["TTU 03.902"],"award-info":[{"award-number":["TTU 03.902"]}],"id":[{"id":"10.13039\/100009139","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Vaccines"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Immunization with radiation-attenuated\n                    <jats:italic>Plasmodium falciparum<\/jats:italic>\n                    (Pf) sporozoites (SPZ) in PfSPZ Vaccine, has provided better vaccine efficacy (VE) against controlled human malaria infection (CHMI) with the same parasites as in the vaccine (homologous) than with genetically distant parasites (heterologous). We sought to identify an immunization regimen that provided similar VE against CHMI with homologous and heterologous Pf for at least 9 weeks in malaria-na\u00efve adults. Such a regimen was identified in part 1 (optimization), an open label study, and confirmed in part 2 (verification), a randomized, double-blind, placebo-controlled study in which VE was assessed by cross-over repeat CHMI with homologous (PfNF54) and heterologous (Pf7G8) PfSPZ at 3 and 9\u201310 weeks. VE was calculated using Bayesian generalized linear regression. In part 1, vaccination with 9\u2009\u00d7\u200910\n                    <jats:sup>5<\/jats:sup>\n                    PfSPZ on days 1, 8, and 29 protected 5\/5 (100%) subjects against homologous CHMI at 3 weeks after the last immunization. In part 2, the same 3-dose regimen protected 5\/6 subjects (83%) against heterologous CHMI at both 3 and 9\u201310 weeks after the last immunization. Overall VE was 78% (95% predictive interval: 57\u201392%), and against heterologous and homologous was 79% (95% PI: 54\u201395%) and 77% (95% PI: 50\u201395%) respectively. PfSPZ Vaccine was safe and well tolerated. A 4-week, 3-dose regimen of PfSPZ Vaccine provided similar VE for 9\u201310 weeks against homologous and heterologous CHMI. The trial is registered with ClinicalTrials.gov, NCT02704533.\n                  <\/jats:p>","DOI":"10.1038\/s41541-022-00510-z","type":"journal-article","created":{"date-parts":[[2022,8,23]],"date-time":"2022-08-23T06:03:05Z","timestamp":1661234585000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":55,"title":["A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9101-2768","authenticated-orcid":false,"given":"Benjamin","family":"Mordm\u00fcller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zita","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mih\u00e1ly","family":"Sulyok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zsofia","family":"Molnar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4692-7835","authenticated-orcid":false,"given":"Albert","family":"Lalremruata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6766-1765","authenticated-orcid":false,"given":"Carlos Lamsfus","family":"Calle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia Granados","family":"Bayon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meral","family":"Esen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Gmeiner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Held","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henri-Lynn","family":"Heimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9508-1787","authenticated-orcid":false,"given":"Tamirat Gebru","family":"Woldearegai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6215-6332","authenticated-orcid":false,"given":"Javier","family":"Ib\u00e1\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Fl\u00fcgge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4716-0311","authenticated-orcid":false,"given":"Rolf","family":"Fendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Kreidenweiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"KC","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tooba","family":"Murshedkar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumana","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouria","family":"Riyahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.","family":"Billingsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. W. Preston","family":"Church","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2946-5456","authenticated-orcid":false,"given":"Thomas L.","family":"Richie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Kim Lee","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0700-9505","authenticated-orcid":false,"given":"Stephen L.","family":"Hoffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3926-4113","authenticated-orcid":false,"given":"Peter G.","family":"Kremsner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,23]]},"reference":[{"key":"510_CR1","unstructured":"World Health Organization. World Malaria Report 2019. 232 (World Health Organization, 2019)."},{"key":"510_CR2","unstructured":"World Health Organization. WHO calls for reinvigorated action to fight malaria (News release). Retrieved from https:\/\/www.who.int\/news\/item\/30-11-2020-who-calls-for-reinvigorated-action-to-fight-malaria (30 November 2020)."},{"key":"510_CR3","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4269\/ajtmh.17-0101","volume":"97","author":"D Khuu","year":"2017","unstructured":"Khuu, D. et al. Malaria-Related Hospitalizations in the United States, 2000\u20132014. Am. J. Trop. Med Hyg. 97, 213\u2013221 (2017).","journal-title":"Am. J. Trop. Med Hyg."},{"key":"510_CR4","unstructured":"European Centre for Disease Prevention and Control. Malaria. In ECDC. Annual epidemiological report for 2018. Retrieved from https:\/\/www.ecdc.europa.eu\/en\/publications-data\/malaria-annual-epidemiological-report-2018 (Stockholm, 2020)."},{"key":"510_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/S1473-3099(16)30326-7","volume":"17","author":"AJ Tatem","year":"2017","unstructured":"Tatem, A. J. et al. The geography of imported malaria to non-endemic countries: a meta-analysis of nationally reported statistics. Lancet Infect. Dis. 17, 98\u2013107 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"510_CR6","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-020-3104-4","volume":"19","author":"J Ahluwalia","year":"2020","unstructured":"Ahluwalia, J., Brooks, S. K., Weinman, J. & Rubin, G. J. A systematic review of factors affecting adherence to malaria chemoprophylaxis amongst travellers from non-endemic countries. Malar. J. 19, 16 (2020).","journal-title":"Malar. J."},{"key":"510_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(15)60721-8","volume":"386","author":"RTS, S Clinical Trials Partnership.","year":"2015","unstructured":"RTS, S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 386, 31\u201345 (2015).","journal-title":"Lancet"},{"key":"510_CR8","unstructured":"World Health Organization. First malaria vaccine in Africa: A potential new tool for child health and improved malaria control. 1\u20134 (2018)."},{"key":"510_CR9","unstructured":"World Health Organaization. WHO recommends groundbreaking malaria vaccine for children at risk [News release]. Retrieved from https:\/\/www.who.int\/news\/item\/06-10-2021-who-recommends-groundbreaking-malaria-vaccine-for-children-at-risk (6 October 2021)."},{"key":"510_CR10","doi-asserted-by":"publisher","unstructured":"Datoo, M. S., et al. Efficacy of a low-dose candidate malaria vaccine, R21 in adjuvant Matrix-M, with seasonal administration to children in Burkina Faso: a randomised controlled trial. Lancet. https:\/\/doi.org\/10.1016\/S0140-6736(21)00943-0 (2021).","DOI":"10.1016\/S0140-6736(21)00943-0"},{"key":"510_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4161\/hv.6.1.10396","volume":"6","author":"SL Hoffman","year":"2010","unstructured":"Hoffman, S. L. et al. Development of a metabolically active,non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum. Vaccines 6, 97\u2013106 (2010).","journal-title":"Hum. Vaccines"},{"key":"510_CR12","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1126\/science.1211548","volume":"334","author":"JE Epstein","year":"2011","unstructured":"Epstein, J. E. et al. Live attenuated malaria vaccine designed to protect through hepatic CD8+T cell immunity. Science 334, 475\u2013480 (2011).","journal-title":"Science"},{"key":"510_CR13","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1126\/science.1241800","volume":"341","author":"RA Seder","year":"2013","unstructured":"Seder, R. A. et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 341, 1359\u20131365 (2013).","journal-title":"Science"},{"key":"510_CR14","doi-asserted-by":"publisher","first-page":"e89154","DOI":"10.1172\/jci.insight.89154","volume":"2","author":"JE Epstein","year":"2017","unstructured":"Epstein, J. E. et al. Protection against Plasmodium falciparum malaria by PfSPZ Vaccine. JCI Insight 2, e89154 (2017).","journal-title":"JCI Insight"},{"key":"510_CR15","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1073\/pnas.1615324114","volume":"114","author":"KE Lyke","year":"2017","unstructured":"Lyke, K. E. et al. Attenuated PfSPZ Vaccine induces strain-transcending T cells and durable protection against heterologous controlled human malaria infection. Proc. Natl Acad. Sci. USA. 114, 2711\u20132716 (2017).","journal-title":"Proc. Natl Acad. Sci. USA."},{"key":"510_CR16","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1016\/S1473-3099(17)30104-4","volume":"17","author":"MS Sissoko","year":"2017","unstructured":"Sissoko, M. S. et al. Safety and efficacy of PfSPZ Vaccine against Plasmodium falciparum via direct venous inoculation in healthy malaria-exposed adults in Mali: a randomised, double-blind phase 1 trial. Lancet Infect. Dis. 17, 498\u2013509 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"510_CR17","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1093\/cid\/ciz1152","volume":"71","author":"SA Jongo","year":"2020","unstructured":"Jongo, S. A. et al. Increase of dose associated with decrease in protection against controlled human malaria infection by PfSPZ Vaccine in Tanzanian adults. Clin. Infect. Dis. 71, 2849\u20132857 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"510_CR18","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S1473-3099(21)00332-7","volume":"22","author":"MS Sissoko","year":"2022","unstructured":"Sissoko, M. S. et al. Safety and efficacy of a three-dose regimen of Plasmodium falciparum sporozoite vaccine in adults during an intense malaria transmission season in Mali: a randomised, controlled phase 1 trial. Lancet Infect. Dis. 22, 377\u2013389 (2022).","journal-title":"Lancet Infect. Dis."},{"key":"510_CR19","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1038\/s41467-022-30882-8","volume":"13","author":"JC Silva","year":"2022","unstructured":"Silva, J. C. et al. Plasmodium falciparum 7G8 challenge provides conservative prediction of efficacy of PfNF54-based PfSPZ Vaccine in Africa. Nat. Commun. 13, 3390 (2022).","journal-title":"Nat. Commun."},{"key":"510_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.4269\/ajtmh.17-0449","volume":"98","author":"A Olotu","year":"2018","unstructured":"Olotu, A. et al. Advancing Global Health through Development and Clinical Trials Partnerships: A Randomized, Placebo-Controlled, Double-Blind Assessment of Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoites Vaccine for Malaria in Healthy Equatoguinean Men. Am. J. Trop. Med. Hyg. 98, 308\u2013318 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR21","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.4269\/ajtmh.18-0835","volume":"100","author":"SA Jongo","year":"2019","unstructured":"Jongo, S. A. et al. Safety and Differential Antibody and T-Cell Responses to the Plasmodium falciparum Sporozoite Malaria Vaccine, PfSPZ Vaccine, by Age in Tanzanian Adults, Adolescents, Children, and Infants. Am. J. Trop. Med. Hyg. 100, 1433\u20131444 (2019).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR22","doi-asserted-by":"publisher","first-page":"e2424","DOI":"10.1093\/cid\/ciaa1294","volume":"73","author":"KE Lyke","year":"2021","unstructured":"Lyke, K. E. et al. Multidose Priming and Delayed Boosting Improve PfSPZ Vaccine Efficacy against Heterologous P. falciparum Controlled Human Malaria Infection. Clin. Infect. Dis. 73, e2424\u2013e2435 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"510_CR23","unstructured":"CIC Research Inc. Survey of international air travelers, U.S. travelers to overseas, January - March 2012. (ed. 1Q12_US_to_Overseas_Banner1_30Sep13.pdf) (National Travel and Tourism Office, 2013)."},{"key":"510_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-019-0708-9","volume":"12","author":"KA Moser","year":"2020","unstructured":"Moser, K. A. et al. Strains used in whole organism Plasmodium falciparum vaccine trials differ in genome structure, sequence, and immunogenic potential. Genome Med 12, 6 (2020).","journal-title":"Genome Med"},{"key":"510_CR25","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1038\/nm.4110","volume":"22","author":"AS Ishizuka","year":"2016","unstructured":"Ishizuka, A. S. et al. Protection against malaria at 1 year and immune correlates following PfSPZ vaccination. Nat. Med. 22, 614\u2013623 (2016).","journal-title":"Nat. Med."},{"key":"510_CR26","doi-asserted-by":"publisher","first-page":"338","DOI":"10.4269\/ajtmh.17-1014","volume":"99","author":"SA Jongo","year":"2018","unstructured":"Jongo, S. A. et al. Safety, Immunogenicity, and Protective Efficacy against Controlled Human Malaria Infection of Plasmodium falciparum Sporozoite Vaccine in Tanzanian Adults. Am. J. Trop. Med. Hyg. 99, 338\u2013349 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR27","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1093\/cid\/ciz925","volume":"71","author":"LC Steinhardt","year":"2020","unstructured":"Steinhardt, L. C. et al. Safety, tolerability, and immunogenicity of PfSPZ Vaccine administered by direct venous inoculation to infants and young children: findings from an age de-escalation, dose-escalation double-blinded randomized, controlled study in western Kenya. Clin. Infect. Dis. 71, 1063\u20131071 (2020).","journal-title":"Clin. Infect. Dis."},{"key":"510_CR28","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1038\/s41591-021-01470-y","volume":"27","author":"M Oneko","year":"2021","unstructured":"Oneko, M. et al. Safety, immunogenicity and efficacy of PfSPZ Vaccine against malaria in infants in western Kenya: a double-blind, randomized, placebo-controlled phase 2 trial. Nat. Med. 27, 1636\u20131645 (2021).","journal-title":"Nat. Med."},{"key":"510_CR29","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.4269\/ajtmh.21-0942","volume":"106","author":"SA Jongo","year":"2022","unstructured":"Jongo, S. A. et al. Multi-Dose Priming Regimens of PfSPZ Vaccine: Safety and Efficacy against Controlled Human Malaria Infection in Equatoguinean Adults. Am. J. Trop. Med. Hyg. 106, 1215\u20131226 (2022).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR30","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.4049\/jimmunol.1202234","volume":"190","author":"K Blom","year":"2013","unstructured":"Blom, K. et al. Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response. J. Immunol. 190, 2150\u20132158 (2013).","journal-title":"J. Immunol."},{"key":"510_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-021-03684-z","volume":"595","author":"A Mwakingwe-Omari","year":"2021","unstructured":"Mwakingwe-Omari, A. et al. Two chemoattenuated PfSPZ malaria vaccines induce sterile hepatic immunity. Nature 595, 289\u2013294 (2021).","journal-title":"Nature"},{"key":"510_CR32","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.smim.2004.08.005","volume":"16","author":"J Stavnezer","year":"2004","unstructured":"Stavnezer, J. & Amemiya, C. T. Evolution of isotype switching. Semin. Immunol. 16, 257\u2013275 (2004).","journal-title":"Semin. Immunol."},{"key":"510_CR33","doi-asserted-by":"publisher","first-page":"S12","DOI":"10.1038\/ni.3607","volume":"17","author":"JH Duarte","year":"2016","unstructured":"Duarte, J. H. Functional switching. Nat. Immunol. 17, S12\u2013S12 (2016).","journal-title":"Nat. Immunol."},{"key":"510_CR34","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1038\/330664a0","volume":"330","author":"L Schofield","year":"1987","unstructured":"Schofield, L. et al. Gamma-interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 330, 664\u2013666 (1987).","journal-title":"Nature"},{"key":"510_CR35","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1073\/pnas.85.2.573","volume":"85","author":"WR Weiss","year":"1988","unstructured":"Weiss, W. R., Sedegah, M., Beaudoin, R. L., Miller, L. H. & Good, M. F. CD8+ T cells (cytotoxic\/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc. Natl Acad. Sci. U. S. A. 85, 573\u2013576 (1988).","journal-title":"Proc. Natl Acad. Sci. U. S. A."},{"key":"510_CR36","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1126\/science.2524877","volume":"244","author":"SL Hoffman","year":"1989","unstructured":"Hoffman, S. L. et al. Sporozoite vaccine induces genetically restricted T cell elimination of malaria from hepatocytes. Science 244, 1078\u20131081 (1989).","journal-title":"Science"},{"key":"510_CR37","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","volume":"165","author":"DL Doolan","year":"2000","unstructured":"Doolan, D. L. & Hoffman, S. L. The complexity of protective immunity against liver-stage malaria. J. Immunol. 165, 1453\u20131462 (2000).","journal-title":"J. Immunol."},{"issue":"Suppl 4","key":"510_CR38","doi-asserted-by":"publisher","first-page":"D13","DOI":"10.1016\/j.vaccine.2015.07.091","volume":"33","author":"SL Hoffman","year":"2015","unstructured":"Hoffman, S. L., Vekemans, J., Richie, T. L. & Duffy, P. E. The march toward malaria vaccines. Vaccine 33(Suppl 4), D13\u201323 (2015).","journal-title":"Vaccine"},{"key":"510_CR39","unstructured":"Diawara, H. \u201cMalaria Vaccination in Pregnancy: PfSPZ Vaccine in Pregnant Women\u201d, Annual Meeting of the American Society of Tropical Medicine & Hygiene, (Virtual presentation) Nov 19 2021."},{"key":"510_CR40","doi-asserted-by":"publisher","first-page":"5","DOI":"10.4269\/ajtmh.2012.12-0613","volume":"88","author":"M Roestenberg","year":"2013","unstructured":"Roestenberg, M. et al. Controlled Human Malaria Infections by Intradermal Injection of Cryopreserved Plasmodium falciparum Sporozoites. Am. J. Trop. Med. Hyg. 88, 5\u201313 (2013).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0817-x","volume":"14","author":"GP Gomez-Perez","year":"2015","unstructured":"Gomez-Perez, G. P. et al. Controlled human malaria infection by intramuscular and direct venous inoculation of cryopreserved Plasmodium falciparum sporozoites in malaria-naive volunteers: effect of injection volume and dose on infectivity rates. Malar. J. 14, 306 (2015).","journal-title":"Malar. J."},{"key":"510_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0628-0","volume":"14","author":"B Mordm\u00fcller","year":"2015","unstructured":"Mordm\u00fcller, B. et al. Direct venous inoculation of Plasmodium falciparum sporozoites for controlled human malaria infection: a dose-finding trial in two centres. Malar. J. 14, 117 (2015).","journal-title":"Malar. J."},{"key":"510_CR43","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1038\/nature21060","volume":"542","author":"B Mordm\u00fcller","year":"2017","unstructured":"Mordm\u00fcller, B. et al. Sterile protection against human malaria by chemoattenuated PfSPZ vaccine. Nature 542, 445\u2013449 (2017).","journal-title":"Nature"},{"key":"510_CR44","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1093\/infdis\/jiz410","volume":"220","author":"MB Laurens","year":"2019","unstructured":"Laurens, M. B. et al. Dose dependent infectivity of aseptic, purified, cryopreserved Plasmodium falciparum 7G8 sporozoites in malaria-naive adults. J. Infect. Dis. 220, 1962\u20131966 (2019).","journal-title":"J. Infect. Dis."},{"key":"510_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-22740-w","volume":"12","author":"Z Sulyok","year":"2021","unstructured":"Sulyok, Z. et al. Heterologous protection against malaria by a simple chemoattenuated PfSPZ vaccine regimen in a randomized trial. Nat. Commun. 12, 2518 (2021).","journal-title":"Nat. Commun."},{"key":"510_CR46","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1016\/S1473-3099(17)30139-1","volume":"17","author":"M Sulyok","year":"2017","unstructured":"Sulyok, M. et al. DSM265 for Plasmodium falciparum chemoprophylaxis: a randomised, double blinded, phase 1 trial with controlled human malaria infection. Lancet Infect. Dis. 17, 636\u2013644 (2017).","journal-title":"Lancet Infect. Dis."},{"key":"510_CR47","doi-asserted-by":"publisher","first-page":"508","DOI":"10.4269\/ajtmh.17-0343","volume":"98","author":"B Lell","year":"2018","unstructured":"Lell, B. et al. Impact of Sickle Cell Trait and Naturally Acquired Immunity on Uncomplicated Malaria after Controlled Human Malaria Infection in Adults in Gabon. Am. J. Trop. Med. Hyg. 98, 508\u2013515 (2018).","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"510_CR48","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1111\/tmi.13357","volume":"25","author":"WG Metzger","year":"2020","unstructured":"Metzger, W. G. et al. Ivermectin for causal malaria prophylaxis: a randomised controlled human infection trial. Trop. Med. Int. Health 25, 380\u2013386 (2020).","journal-title":"Trop. Med. Int. Health"},{"key":"510_CR49","doi-asserted-by":"publisher","first-page":"e1009594","DOI":"10.1371\/journal.ppat.1009594","volume":"17","author":"SC Murphy","year":"2021","unstructured":"Murphy, S. C. et al. PfSPZ-CVac efficacy against malaria increases from 0 to 75% when administered in the absence of erythrocyte stage parasitemia: A randomized, placebo-controlled trial with controlled human malaria infection. PLoS Pathog. 17, e1009594 (2021).","journal-title":"PLoS Pathog."},{"key":"510_CR50","doi-asserted-by":"publisher","first-page":"2544","DOI":"10.1093\/cid\/ciz740","volume":"70","author":"J Achan","year":"2019","unstructured":"Achan, J. et al. Serologic markers of previous malaria exposure and functional antibodies inhibiting parasite growth are associated with parasite kinetics following a Plasmodium falciparum controlled human infection. Clin. Infect. Dis. 70, 2544\u20132552 (2019).","journal-title":"Clin. Infect. Dis."},{"key":"510_CR51","doi-asserted-by":"publisher","first-page":"155","DOI":"10.12688\/wellcomeopenres.14909.2","volume":"3","author":"MC Kapulu","year":"2019","unstructured":"Kapulu, M. C., Njuguna, P. & Hamaluba, M. M. Controlled Human Malaria Infection in Semi-Immune Kenyan Adults (CHMI-SIKA): a study protocol to investigate in vivo Plasmodium falciparum malaria parasite growth in the context of pre-existing immunity. Wellcome Open Res 3, 155 (2019).","journal-title":"Wellcome Open Res"},{"key":"510_CR52","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-234","volume":"13","author":"F Joanny","year":"2014","unstructured":"Joanny, F., Lohr, S. J., Engleitner, T., Lell, B. & Mordmuller, B. Limit of blank and limit of detection of Plasmodium falciparum thick blood smear microscopy in a routine setting in Central Africa. Malar. J. 13, 234 (2014).","journal-title":"Malar. J."}],"container-title":["npj Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00510-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00510-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00510-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,24]],"date-time":"2022-11-24T13:47:24Z","timestamp":1669297644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41541-022-00510-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,23]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["510"],"URL":"https:\/\/doi.org\/10.1038\/s41541-022-00510-z","relation":{},"ISSN":["2059-0105"],"issn-type":[{"value":"2059-0105","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,23]]},"assertion":[{"value":"19 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NKC, SC, PR, LWPC, TLR, BKLS, and SLH are salaried, full-time employees of Sanaria, the developer and sponsor of Sanaria PfSPZ Vaccine and PfSPZ Challenge. SLH and BKLS also have financial interests in Sanaria. BKLS and SLH are inventors on patents and patent applications that have been assigned to Sanaria. BM and PGK received funding from DZIF to conduct the trial. All other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"100"}}